Policy Watch: 20 Regulatory Updates — April 25, 2026
Policy WatchApril 25, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal Register Schedules…
Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine in Schedule I
The DEA drug scheduling updates include placing 3-methoxyphencyclidine in Schedule I due to its high abuse potential. This synthetic phencyclidine analog lacks accepted medical use. Understanding these updates helps clinicians anticipate regulatory…
Policy Watch: 10 Regulatory Updates — March 19, 2026
This update covers DEA synthetic opioid scheduling and regulatory changes relevant to cannabis clinicians. The focus is on new Schedule I placements and their clinical implications. These regulatory updates inform patient care and research considerations.
Policy Watch: 5 Regulatory Updates — March 19, 2026
This update covers DEA scheduling synthetic opioids 2026 regulatory actions affecting controlled substances. These changes influence clinical practices involving controlled drugs. Cannabis medicine remains primarily governed by state laws and federal…
Policy Watch: 20 Regulatory Updates — March 14, 2026
This Policy Watch covers the marijuana rescheduling federal update alongside 20 regulatory items relevant to cannabis medicine. The DEA's rescheduling of marijuana from Schedule I to Schedule III marks a significant shift in federal cannabis policy.…
Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
The temporary placement of bromazolam in Schedule I highlights regulatory efforts to control novel psychoactive substances. This scheduling reflects concerns about bromazolam's abuse potential and lack of accepted medical use. Clinicians should be aware…
Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I
The DEA has placed 2-Methyl AP-237, a synthetic opioid, into Schedule I due to its high abuse potential. This synthetic opioid scheduling reflects federal efforts to control emerging drugs rapidly. Clinicians should monitor these developments for…
Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I
The temporary placement of N-Desethyl Isotonitazene in Schedule I reflects DEA efforts to control emerging synthetic opioids. This scheduling addresses drugs of abuse with no recognized medical use. Clinicians should stay informed about such regulatory…
Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I
Nitazene synthetic opioids such as N-pyrrolidino metonitazene and N-pyrrolidino protonitazene have been temporarily placed in Schedule I. These substances pose significant overdose risks and are emerging threats in illicit drug supplies. Clinicians…
Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I
This article discusses the schedules of controlled substances focusing on ethylphenidate's placement in Schedule I. The scheduling reflects concerns about synthetic stimulants and abuse potential. Clinicians should be aware of regulatory updates on…